Pulse Biosciences Inc (PLSE)
Pulse Biosciences, Inc. is a healthcare company focused on bioelectric medicine and listed on the NASDAQ under the ticker PLSE as common stock. The company develops the nPulse platform, a nanosecond pulsed-field ablation delivery system designed for multiple clinical uses. Its product set includes a system for treating benign skin lesions, a percutaneous electrode system for soft tissue ablation in surgical settings, a cardiac surgical clamp for atrial fibrillation procedures, a cardiac catheter system intended to deliver circumferential ablation in a single treatment cycle, and a console platform built to support physician workflow. Founded in 2014 and headquartered in Miami, Florida, the company adopted its current name in December 2015 after operating as Electroblate, Inc.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-PLSE
|
$16.99
|
-44.5% Downside
|
Overvalued
|
$30.67
|
0.2% Upside
|
Fair
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 12, 2026
|
-28.4x
|
31.9x
|
2,815.4x
|
2.004 B
|
2.053 B
|
0.4%
|
26.7%
|
67.6
|
—
|
74.4%
|
